Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized AI-assisted treatment in neovascular AMD
2024-518482-99-01Phase 4Authorised
- Sponsor
- Medical University of Vienna
- Start
- Jan 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in exudative macular degeneration comparing AI-guided aflibercept (Eylea), AI-guided ranibizumab (Lucentis) and AI-guided brolucizumab (Beovu) (3 arms). Primary endpoint: Number of anti-VEGF injections. Planned start Jan 2025; status: authorised.
02
Drugs
afliberceptranibizumabbrolucizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2024-518482-99-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518482-99-01.